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Neoadjuvant chemotherapy 
plus intensity-modulated radiotherapy 
versus concurrent chemoradiotherapy 
plus adjuvant chemotherapy for the treatment 
of locoregionally advanced nasopharyngeal 
carcinoma: a retrospective controlled study
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Abstract 
Background: In the era of intensity‑modulated radiotherapy (IMRT), the role of neoadjuvant chemotherapy (NAC) 
for locoregionally advanced nasopharyngeal carcinoma (NPC) is under‑evaluated. The aim of this study was to com‑
pare the efficacy of NAC plus IMRT and concurrent chemoradiotherapy (CCRT) plus adjuvant chemotherapy (AC) on 
locoregionally advanced NPC.
Methods: Between January 2004 and December 2008, 240 cases of locoregionally advanced NPC confirmed by 
pathologic assessment in Sun Yat‑sen University Cancer Center were reviewed. Of the 240 patients, 117 received NAC 
followed by IMRT, and 123 were treated with CCRT plus AC. The NAC + IMRT group received a regimen that included 
cisplatin and 5‑fluorouracil (5‑FU). The CCRT + AC group received cisplatin concurrently with radiotherapy, and 
subsequently received adjuvant cisplatin and 5‑FU. The survival rates were assessed by Kaplan–Meier analysis, and the 
survival curves were compared using a log‑rank test. Multivariate analysis was conducted using the Cox proportional 
hazard regression model.
Results: The 5‑year overall survival (OS), locoregional relapse‑free survival (LRRFS), distant metastasis‑free survival 
(DMFS), and disease‑free survival (DFS) were 78.0, 87.9, 79.0, and 69.8%, respectively, for the NAC + IMRT group and 
78.7, 84.8, 76.2, and 65.6%, respectively, for the CCRT + AC group. There were no significant differences in survival 
between the two groups. In multivariate analysis, age (<50 years vs. ≥50 years) and overall stage (III vs. IV) were found 
to be independent predictors for OS and DFS; furthermore, the overall stage was a significant prognostic factor for 
DMFS. Compared with the CCRT + AC protocol, the NAC + IMRT protocol significantly reduced the occurrence rates 
of grade 3–4 nausea–vomiting (6.5 vs. 1.5%, P = 0.023) and leukopenia (9.7 vs. 0.8%, P = 0.006).
Conclusions: The treatment outcomes of the NAC + IMRT and CCRT + AC groups were similar. Distant metastasis 
remained the predominant mode of treatment failure.
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Background
Nasopharyngeal carcinoma (NPC) is endemic in South 
China and Southeast Asia, with an annual incidence of 
15–50 cases per 100,000 [1]. NPC mortality in China, 
especially in South China, was also at high levels [2]. 
Radiotherapy is the primary treatment modality for NPC, 
and the outcome for patients with early-stage disease is 
usually favorable; however, the response of locoregionally 
advanced NPC to radiotherapy is unsatisfactory [3].
Combining chemotherapy and radiotherapy is a rea-
sonable strategy for improving the long-term outcome of 
locoregionally advanced NPC. The Intergroup 0099 Study 
(IGS) was the first randomized, controlled trial to achieve 
a significant improvement in the 3-year overall survival 
(OS) for stages III-IVb NPC patients by adding concur-
rent and adjuvant chemotherapy to conventional radio-
therapy [4]. Since then, this regimen has been deemed the 
standard of care for advanced NPC. However, there have 
been serious concerns regarding the applicability of the 
IGS results, and the outcomes of several randomized, con-
trolled trials attempting to verify the efficacy of concurrent 
chemoradiotherapy (CCRT) plus adjuvant chemotherapy 
(AC) were conflicting [5–9]. With the advent of intensity-
modulated radiotherapy (IMRT), local control has been 
substantially improved, and distant metastasis is now the 
main cause of treatment failure [10]. Further improve-
ments in systemic control by the use of concurrent chemo-
therapy is unlikely because of drug-related toxic effects 
[7]; data from several published studies [11, 12] show that 
AC does not translate to significant improvements in pro-
longing OS and reducing distant metastatic rate (DMR). 
One strategy for treatment improvement is to change the 
sequence from concurrent-adjuvant to addition of neo-
adjuvant chemotherapy (NAC) prior to radiotherapy. It is 
important to address the efficacy of NAC because meta-
analyses showed that NAC could significantly reduce both 
locoregional and distant failures [13, 14]. A pooled meta-
analysis of two trials by Chua et al. [13] noted that modest 
improvements in relapse-free survival and disease-specific 
survival could be achieved by NAC. Another meta-analysis 
by Ouyang et  al. [14] revealed significant treatment effi-
cacy in terms of OS and DMR for NAC.
Because most of these studies were based on the non-
IMRT technique, the role of NAC plus IMRT for locore-
gionally advanced NPC in the era of IMRT is unknown. 
The aim of this study was to compare the efficacy of 
NAC plus IMRT with CCRT plus AC on locoregionally 
advanced NPC.
Methods
Patients
Inclusion criteria were as follows: pathologically diag-
nosed non-keratinizing or undifferentiated carcinoma of 
the nasopharynx (World Health Organization [WHO] 
type II or III); age of 18–65 years; stages III-IVb disease 
according to the 2002 Union for International Cancer 
Control (UICC) Staging System; no evidence of distant 
metastasis; Karnofsky performance score ≥70; normal 
hematologic function [white blood cell (WBC) count 
≥4.0 × 109/L, platelet (PLT) count ≥100 × 109/L]; nor-
mal hepatic function [total bilirubin (TBIL) and alanine 
aminotransferase (ALT) <2 times the normal values]; 
normal renal function [creatinine (Cr) <1.5 times the 
normal value]; receiving radical IMRT at initial diagno-
sis; and receiving NAC with cisplatin and 5-fluorouracil 
(5-FU) for two cycles or receiving concurrent chemo-
therapy with cisplatin for two cycles plus AC with cispl-
atin and 5-FU for two cycles.
Radiotherapy
All patients were immobilized in the supine position with 
a head, neck, and shoulder thermoplastic mask. Two sets 
of images, with and without contrast, were obtained from 
the computed tomography (CT) simulator for treatment 
planning. All patients were scanned with serial 3-mm 
slices from the vertex through the clavicles. Inverse 
IMRT planning was performed using the Corvus system, 
version 3.0 (Peacock, Nomos, Deer Park, IL, USA), and 
a dynamic, multileaf, intensity-modulating collimator 
(MIMiC; Nomos Corp., Sewickly, PA, USA) was used for 
planning and treatment. The gross tumor volumes of the 
nasopharynx (GTVnx) and positive neck lymph nodes 
(GTVnd) were delineated according to our previously 
described institutional treatment protocol [15], which 
is in agreement with the International Commission on 
Radiation Units and Measurements Reports 50 [16] and 
Reports 62 [17]. The first clinical tumor volume (CTV1) 
was defined as the GTVnx plus a margin of 5–10 mm for 
potential microscopic spread, including the entire naso-
pharyngeal mucosa plus a 5-mm submucosal volume. 
The second CTV (CTV2) was defined by adding a margin 
of 5–10 mm to CTV1 and included the following regions, 
which needed prophylactic irradiation: retropharyngeal 
lymph node regions, the clivus, skull base, pterygoid fos-
sae, parapharyngeal space, inferior sphenoid sinus, pos-
terior edge of the nasal cavity, maxillary sinuses, and the 
lymphatic drainage area. The planning target volume 
Keywords: Nasopharyngeal carcinoma, Intensity‑modulated radiotherapy, Neoadjuvant chemotherapy, Concurrent 
chemoradiotherapy, Adjuvant chemotherapy
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(PTV) for GTVs and CTVs were generated automati-
cally by adding a 5-mm margin after delineation of tumor 
targets according to the immobilization and localization 
uncertainties. The prescribed dose was 68–70 Gy to the 
PTV of the GTVnx (PTVnx), 64–68 Gy to the PTV of the 
GTVnd (PTVnd), 60 Gy to the PTV of the CTV1 (PTV1), 
and 54  Gy to the PTV of the CTV2 (PTV2) in 30 frac-
tions. All patients were treated with one fraction daily 
over 5 days per week.
Chemotherapy
For the NAC +  IMRT group, two NAC cycles, consist-
ing of cisplatin (80 mg/m2 intravenous infusion on day 1) 
and 5-FU (4  g/m2 daily as a 120-h intravenous infusion 
on days 1–5), were administered at an interval of 3 weeks 
before radiotherapy.
For the CCRT  +  AC group, two concurrent chemo-
therapy cycles, consisting of cisplatin (80  mg/m2 intra-
venous infusion on days 1 and 22), were administered 
at an interval of 3  weeks during radiotherapy; 2 subse-
quent AC cycles, consisting of cisplatin (80 mg/m2 intra-
venous infusion on day 1) and 5-FU (4  g/m2 daily as a 
120-h intravenous infusion on days 1–5), were admin-
istered at an interval of 3 weeks after the completion of 
radiotherapy.
Patient assessment and follow‑up
Clinical evaluation of the efficacy of therapy was based 
on the Response Evaluation Criteria in Solid Tumors 
(RECIST) v1.1 [18]. Acute and late adverse events were 
assessed according to the Common Terminology Cri-
teria for Adverse Events (CTCAE) v3.0 [19]. Patients 
were evaluated weekly during radiotherapy and every 
3  months for the first 3  years, every 6  months for the 
fourth and fifth years, and every year thereafter. Follow-
up evaluation included physical examination of the head 
and neck, nasopharyngeal endoscopy, chest radiography, 
abdominal ultrasound, Epstein–Barr virus (EBV) sero-
logical testing, and magnetic resonance imaging (MRI) or 
CT of the head and neck region. CT scans of the abdomi-
nopelvic cavity or chest, bone scans, and positron emis-
sion tomography scans were conducted when clinically 
indicated.
Statistical analysis
The SPSS 16.0 statistical software (SPSS Inc., Chicago, 
IL, USA) was used. The Chi square analysis was used 
to compare occurrence rates of adverse events and cat-
egorical variables. The means of continuous variables 
were compared using the Student’s t test. The study end-
points of OS, LRRFS, DMFS, and DFS were determined 
by patient death, relapse of a local or nodal tumor, occur-
rence of distant metastasis, and occurrence of relapse 
or distant metastasis respectively. The time-to-event for 
each endpoint was calculated from the date of comple-
tion of treatment to the occurrence date of the event 
using the Kaplan–Meier method. Statistical differences 
in endpoints were estimated using the log-rank test. The 
multivariate analysis was conducted by the Cox propor-
tional hazard regression model. A two-tailed P value of 
less than 0.05 was considered significant.
Results
Patient characteristics
Between January 2004 and December 2008, clinical data 
of 240 NPC patients treated in the Sun Yat-sen University 
Cancer Center who met all of the criteria were retrospec-
tively analyzed. Of these patients, 175 were males and 65 
were females. The median age was 44 years. Of the 240 
patients, 117 received NAC followed by IMRT, and 123 
were treated with CCRT plus AC. No significant differ-
ences were found between the two groups in baseline 
characteristics (Table 1).
Treatment and compliance
All patients completed the full course of radiotherapy. 
In the NAC +  IMRT group, all patients completed two 
cycles of NAC. In the CCRT  +  AC group, all patients 
completed two cycles of concurrent chemotherapy and 
two cycles of AC.
Clinical response
After two cycles of NAC with cisplatin plus 5-FU, 
five patients (4.3%) had a complete response (CR), 
and 93 (79.5%) had a partial response (PR) in the 
NAC +  IMRT group. Three months after radiotherapy, 
the effective rates (CR plus PR) were 98.3% (115/117) 
in the NAC +  IMRT group and 98.4% (121/123) in the 
CCRT + AC group (P = 1.000).
Patterns of treatment failure
The failure patterns, locoregional or distant, in the 
NAC  +  IMRT and CCRT  +  AC groups were similar 
(Table 2).
Acute and late toxicities
Acute toxicities during radiotherapy were well tolerated 
by the entire group. Compared with the CCRT  +  AC 
group, the NAC + IMRT group had significantly reduced 
occurrence rates of grades 3–4 nausea–vomiting (6.5 vs. 
1.5%, P = 0.023) and leukopenia (9.7 vs. 0.8%, P = 0.006). 
No significant differences in anemia, thrombocytopenia, 
liver dysfunction, and mucositis were found between the 
two groups (Table  3). The most common late toxicities 
were xerostomia, hear loss, skin dystrophy, subcutane-
ous fibrosis, and temporal lobe injury (TLI). Ten patients 
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(4.2%) developed TLI. Among them, 4 had radiation 
injuries in unilateral temporal lobes, and 6 in bilateral 
temporal lobes. No significant differences in late tox-
icities were found between the two groups. However, in 
the CCRT + AC group, 4 patients (3.3%) had grades 3–4 
hear loss, and 2 (1.6%) had grades 3–4 TLI.
Survival analysis
The 5-year OS, LRRFS, DMFS, and DFS rates were 78.0, 
87.9, 79.0, and 69.8%, respectively, for the NAC + IMRT 
group, and 78.7, 84.8, 76.2, and 65.6%, respectively, for the 
CCRT + AC group. There were no significant differences 
in survival between the two groups (Fig. 1). Subset analy-
ses revealed that the differences in OS, LRRFS, DMFS, 
and DFS were significant in all subsets (Table 4).
Prognostic factors
The various potential prognostic factors for predicting 
LRRFS, DMFS, DFS, and OS rates, including gender, 
age, WHO histology, T stage, N stage, overall stage, and 
treatment, were evaluated in univariate and multivariate 
analysis. In univariate analysis, age and overall stage were 
significant prognostic factors for OS, DMFS, and DFS 
(Table  5). In multivariate analysis, age and overall stage 
Table 1 Characteristics of the 240 patients with locoregionally advanced nasopharyngeal carcinoma (NPC)
NAC neoadjuvant chemotherapy, IMRT intensity-modulated radiotherapy, CCRT concurrent chemoradiotherapy, AC adjuvant chemotherapy, WHO World Health 
Organization
Characteristic NAC + IMRT [cases (%)] CCRT + AC [cases (%)] χ2 P
Total 117 123
Age (years) 0.199 0.656
 <50 83 (70.9) 84 (68.3)
 ≥50 34 (29.1) 39 (31.7)
Gender 1.148 0.284
 Male 89 (76.1) 86 (69.9)
 Female 28 (23.9) 37 (30.1)
T stage 1.029 0.794
 T1 4 (3.4) 4 (3.3)
 T2 11 (9.4) 14 (11.4)
 T3 57 (48.7) 65 (52.8)
 T4 45 (38.5) 40 (32.5)
N stage 3.578 0.311
 N0 22 (18.8) 27 (22.0)
 N1 40 (34.2) 50 (40.6)
 N2 46 (39.3) 42 (34.1)
 N3 9 (7.7) 4 (3.3)
Clinical stage 2.256 0.133
 III 65 (55.6) 80 (65.0)
 IV 52 (44.4) 43 (35.0)
WHO histology 0.313 0.576
 II 13 (11.1) 11 (8.9)
 III 104 (88.9) 112 (91.1)
Table 2 Patterns of disease failure in patients treated with NAC plus IMRT vs. CCRT plus AC
Abbreviations as in Table 1
Failure pattern NAC + IMRT [cases (%)] CCRT + AC [cases (%)] P
Locoregional relapse only 11 (9.4) 12 (9.8) 0.926
Distant metastases only 22 (18.8) 26 (21.1) 0.651
Both locoregional relapse and distant metastases 2 (1.7) 6 (4.9) 0.314
Death 28 (23.9) 37 (30.1) 0.284
Page 5 of 9Qiu et al. Chin J Cancer  (2016) 35:2 
Table 3 Treatment-related toxicities in patients with locoregionally advanced NPC treated with NAC plus IMRT vs. CCRT 
plus AC
Abbreviations as in Table 1
Toxicity NAC + IMRT
[cases (%)]
CCRT + AC
[cases (%)]
χ2 P
Grade 3/4 acute toxicities
 Leukopenia 1 (0.9) 12 (9.8) 7.618 0.006
 Anemia 0 3 (2.4) 1.252 0.263
 Thrombocytopenia 1 (0.9) 4 (3.3) 0.719 0.397
 Hepatotoxicity 0 1 (0.8) 0.000 1.000
 Nausea–vomiting 2 (1.7) 10 (8.1) 5.204 0.023
 Mucositis 5 (4.3) 8 (6.5) 0.582 0.445
Late toxicities
 Skin dystrophy 37 (31.6) 51 (41.5) 2.500 0.114
 Subcutaneous fibrosis 26 (22.2) 29 (23.6) 0.062 0.803
 Xerostomia 68 (58.1) 85 (69.1) 3.132 0.077
 Hear loss 54 (46.2) 64 (52.0) 0.829 0.363
 Temporal lobe injury 4 (3.4) 6 (4.9) 0.059 0.809
Fig. 1 Kaplan–Meier estimates of the survival of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated by neoadjuvant 
chemotherapy (NAC) plus intensity‑modulated radiotherapy (IMRT) vs. concurrent chemoradiotherapy (CCRT) plus adjuvant chemotherapy (AC). a 
overall survival; b locoregional relapse‑free survival; c distant metastasis‑free survival; d disease‑free survival. There were no significant differences in 
survival between the two groups
Page 6 of 9Qiu et al. Chin J Cancer  (2016) 35:2 
were found to be the independent predictors for OS and 
DFS, and overall stage was a significant prognostic fac-
tor for DMFS (Table 6). No significant prognostic factors 
were found for LRRFS in either univariate or multivariate 
analysis.
Discussion
For locoregionally advanced NPC, the present study 
demonstrated that NAC plus IMRT and CCRT plus 
AC resulted in similar outcomes in terms of 5-year OS, 
LRRFS, DMFS, and DFS rates. A subgroup analysis indi-
cated that the effect of concurrent and adjuvant chemo-
therapy on OS, LRRFS, DMFS, and DFS was insignificant 
in all subsets.
CCRT has been considered the standard of care for 
locoregionally advanced NPC [20]. Although the effi-
cacy of chemotherapy delivered concurrently with con-
ventional radiotherapy has been repeatedly proven [4, 6, 
Table 4 Subset analyses on  tumor control in  patients with  locoregionally advanced NPC treated by  NAC plus  IMRT vs. 
CCRT plus AC
OS overall survival, LRRFS locoregional relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival, HR hazard ratio, CI confidence interval. 
Other abbreviations as in Table 1
Stage OS LRRFS DMFS DFS
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Overall 1.14 (0.70–1.87) 0.599 1.27 (0.62–2.59) 0.515 1.22 (0.72–2.08) 0.456 1.16 (0.74–1.81) 0.517
III 1.52 (0.68–3.39) 0.308 2.23 (0.79–6.24) 0.119 1.62 (0.69–3.80) 0.259 1.62 (0.83–3.16) 0.155
IV 1.04 (0.55–1.96) 0.912 0.65 (0.21–1.98) 0.440 1.11 (0.55–2.21) 0.777 0.92 (0.50–1.70) 0.789
T1–2 0.70 (0.14–3.48) 0.663 50.52 (0–6.22 × 108) 0.386 0.48 (0.11–2.17) 0.332 0.65 (0.16–2.60) 0.537
T3–4 1.23 (0.73–2.07) 0.430 1.25 (0.61–2.57) 0.548 1.41 (0.80–2.49) 0.237 1.27 (0.79–2.02) 0.325
N0–1 1.17 (0.60–2.28) 0.638 1.38 (0.55–3.47) 0.487 1.12 (0.54–2.32) 0.766 1.08 (0.60–1.94) 0.797
N2–3 1.11 (0.52–2.37) 0.783 1.01 (0.31–3.30) 0.990 1.42 (0.66–3.07) 0.370 1.27 (0.64–2.52) 0.487
Table 5 Univariate analysis of prognostic factors for patients with locoregionally advanced NPC
Variate 5‑year survival rate (%)
OS P LRRFS P DMFS P DFS P
Gender 0.173 0.587 0.077 0.224
 Male 75.8 87.1 75.3 65.9
 Female 88.0 83.3 85.8 74.0
Age (years) 0.002 0.489 0.025 0.007
 <50 82.8 87.0 81.5 73.1
 ≥50 68.6 84.6 68.4 55.6
WHO histology 0.362 0.564 0.526 0.549
 Type II 87.1 90.3 83.3 74.5
 Type III 77.5 85.8 76.9 66.9
T stage 0.213 0.070 0.773 0.299
 T1–2 84.4 96.4 81.3 78.1
 T3–4 77.4 84.6 76.9 66.0
N stage 0.934 0.475 0.414 0.994
 N0–1 80.8 85.2 79.4 67.2
 N2–3 75.1 87.8 74.9 68.2
Overall stage <0.001 0.518 0.001 0.004
 III 85.6 87.7 84.9 74.7
 IV 66.5 83.5 65.3 56.2
Treatment 0.599 0.515 0.456 0.517
 NAC + IMRT 78.0 87.9 79.0 69.8
 CCRT + AC 78.7 84.8 76.2 65.6
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21], the most effective combination of chemotherapy and 
IMRT has not been well established.
Three retrospective studies have evaluated the contri-
bution of chemotherapy for patients with NPC treated 
with IMRT [22–24]. Lin et  al. [22] reported that IMRT 
following NAC for locoregionally advanced NPC pro-
vided a favorable outcome in terms of 3-year local/
regional control, metastasis-free survival (MFS), DFS, 
and OS; furthermore, their results suggested that con-
current chemotherapy offered no significant value for 
further improvement of local and regional control to 
IMRT following NAC. Su et  al. [23] demonstrated that 
patients with locoregionally advanced NPC had simi-
lar OS, MFS, and DFS when treated with IMRT-based 
modalities, including IMRT alone, NAC plus IMRT, 
IMRT plus AC, CCRT alone, NAC plus CCRT, and 
CCRT plus AC. Another retrospective study assigned 
276 patients with locoregionally advanced NPC to com-
pare IMRT alone with NAC plus IMRT, CCRT alone, 
and NAC plus CCRT [24]. The results revealed that 
the addition of concurrent or neoadjuvant-concurrent 
chemotherapy to IMRT prolonged relapse-free survival 
(RFS) or DFS for patients with locoregionally advanced 
NPC, whereas NAC provided no significant benefit for 
OS, MFS, RFS, and DFS.
In the current retrospective cohort study, NAC plus 
IMRT produced a superb outcome similar to CCRT 
plus AC in terms of locoregional control in patients with 
locoregionally advanced NPC (87.9 vs. 84.8%, P = 0.515). 
We hypothesized that the application of IMRT would 
improve the local control rate, which may “counteract” 
the effect of CCRT on improving the local control rate 
and survival rate. In addition, NAC could reduce hypoxia 
in the primary site and metastatic lymph nodes by 
shrinking the tumor, which could increase radio-sensitiv-
ity and increase locoregional control [25]. After 2 cycles 
of NAC with cisplatin plus 5-FU, 5 patients (4.3%) had 
CR, and 93 (79.5%) had PR in the NAC + IMRT group.
Although the use of IMRT has produced significant 
improvements in LRRFS, effective treatment of distant 
metastases remains an important problem to be solved. 
In the present study, 23 patients experienced a local or 
regional relapse, and 48 developed a distant metastasis. 
Distant metastasis remained the predominant mode of 
treatment failure, which was consistent with the results 
of other reports [26, 27]. Our results demonstrated that 
NAC plus IMRT achieved similar DMFS compared 
with CCRT plus AC (79.0 vs. 76.2%, P  =  0.456). The 
main goal of NAC is to eradicate distant micrometas-
tases [28]. Given the high distant failure rate associated 
with NPC, it is logical to expect a decline in distant 
failure with the use of NAC. A recent meta-analysis 
that emphasized the use of NAC revealed that NAC 
could effectively enhance OS and reduce DMR [14]. 
However, both the drug dose and course necessary to 
eradicate all distant micrometastases are still unknown. 
As a result, we recommend further investigation on the 
optimal regimen of NAC for locoregionally advanced 
NPC.
A multivariable analysis for prognostic factors was 
also performed in the present study. OS and DFS were 
both independently affected by age and overall stage, 
and DMFS was only affected by overall stage. It is well 
known that overall stage is undoubtedly the most impor-
tant prognostic factor for predicting the survival of NPC 
patients [29, 30].
Despite of the proven efficacy of chemotherapy deliv-
ered concurrently with conventional radiation, the 
combined treatment strategy comes with substantial 
adverse effects. In the pivotal INT-0099 trial, the pro-
portions of patients who could complete the scheduled 
concurrent and adjuvant chemotherapy were only 63 
and 55%, respectively, due to excess toxicity [4]. Similar 
results on treatment-related toxicities have been docu-
mented in retrospective and randomized studies [6, 21, 
31].
Table 6 Multivariate analysis of prognostic factors for patients with locoregionally advanced NPC
Variable OS LRRFS DMFS DFS
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Gender (males vs. females) 0.63 (0.32–1.26) 0.191 1.25 (0.55–2.85) 0.588 0.50 (0.22–1.11) 0.087 0.71 (0.39–1.30) 0.265
Age (<50 vs. ≥50 years) 1.92 (1.17–3.15) 0.010 1.31 (0.62–2.77) 0.486 1.59 (0.93–2.72) 0.092 1.70 (1.08–2.67) 0.022
WHO histology (Type II vs. Type III) 1.87 (0.67–5.21) 0.229 1.54 (0.36–6.50) 0.561 1.59 (0.57–4.44) 0.379 1.22 (0.77–1.92) 0.433
T stage (T1–2 vs. T3–4) 1.39 (0.52–3.67) 0.512 5.69 (071–45.81) 0.102 1.00 (0.39–2.59) 0.999 1.36 (0.58–3.19) 0.475
N stage (N0–1 vs. N2–3) 1.36 (0.79–2.37) 0.270 1.13 (0.51–2.47) 0.768 1.59 (0.88–2.87) 0.126 1.29 (0.78–2.13) 0.322
Overall stage (III vs. IV) 2.50 (1.47–4.26) 0.001 1.05 (0.51–2.17) 0.897 2.54 (1.41–4.58) 0.002 1.80 (1.12–2.89) 0.016
Treatment (NAC + IMRT vs. CCRT + AC) 1.23 (0.74–2.03) 0.426 1.34 (0.65–2.77) 0.436 1.35 (0.78–2.32) 0.281 1.40 (0.60–3.25) 0.397
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In the present study, the group of patients who 
received CCRT plus AC had significantly more 
severe leukopenia and nausea–vomiting than patients 
who received NAC plus IMRT. In the CCRT  +  AC 
group, most of the grades 3–4 nausea–vomiting 
occurred during the CCRT phase. Compared with 
the CCRT + AC group, the NAC +  IMRT group had 
less gastrointestinal and hematologic toxicities. Stud-
ies by Lin et  al. [22] and Sun et  al. [32] also demon-
strated that the total occurrence rates of grade 3 or 4 
acute toxicities in patients receiving concurrent chem-
otherapy was higher than those who received IMRT 
alone. No significant differences in late toxicities were 
found between the two groups. In our study, in the 
NAC  +  IMRT group, skin dystrophy, subcutaneous 
fibrosis, xerostomia, and TLI were mild (grades 1–2); 
however, in the CCRT +  AC group, 4 patients (3.3%) 
had grades 3–4 hear loss, and 2 (1.6%) had grades 3–4 
TLI. One possible explanation for milder toxicities in 
the NAC + IMRT group may be that NAC was likely to 
reduce primary tumor volume for patients with intrac-
ranial invasion, and re-planning of the delineation for 
tumor volume after NAC could better protect critical 
normal tissue and reduce IMRT-associated adverse 
events [33].
These results demonstrated that a regimen of CCRT 
plus AC that significantly increases the probability 
and severity of treatment-related adverse events might 
not be essential for the treatment of NPC if NAC and 
IMRT are used instead. We hypothesize that omission 
of concurrent-adjuvant chemotherapy may be possi-
ble, and effective disease control in the primary area 
and neck lymph nodes can be achieved with improve-
ment in radiation technology and use of sequential 
chemotherapy. Further randomized clinical trials are 
necessary for the establishment of the most effective 
combination of chemotherapy and IMRT to improve 
the prognosis of patients with locoregionally advanced 
NPC.
Conclusions
The treatment outcomes of NAC plus IMRT and CCRT 
plus AC for locoregionally advanced NPC were simi-
lar. Distant metastasis remained the predominant mode 
of treatment failure. The most effective combination of 
chemotherapy and IMRT needs to be established through 
further randomized clinical trials.
Authors’ contributions
WQ participated in the design of the study, performed the statistical analysis, 
and drafted the manuscript. PH participated in the design of the study and 
performed the statistical analysis. JS participated in the acquisition of data. 
HX participated in the acquisition of data. CZ participated in the design of the 
study and performed the statistical analysis. KC conceived of the study, and 
participated in its design and coordination, and helped to draft the manu‑
script. All authors read and approved the final manuscript.
Author details
1 Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncol‑
ogy in South China, Collaborative Innovation Center of Cancer Medicine, Sun 
Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China. 
2 Department of Radiation Oncology, The Second Hospital of Tianjin Medical 
University, Tianjin 300211, P.R. China. 
Acknowledgements
This work was supported by grants from Sun Yat‑sen University Clinical 
Research 5010 Program (No. 2015010), the Fundamental Research Funds for 
the Central Universities (No. 15ykpy36), Clinical Research of Special Funds of 
Wu Jieping Medical Foundation (no. 320.6750.14270).
Competing interests
The authors declare that they have no competing interests.
Received: 5 August 2015   Accepted: 15 October 2015
References
 1. Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a 
“Cantonese cancer”? Chin J Cancer. 2010;29(5):517–26.
 2. Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX, Chen WQ. Nasopharyn‑
geal carcinoma incidence and mortality in China in 2010. Chin J Cancer. 
2014;33(8):381–7. doi:10.5732/cjc.014.10086.
 3. Ma J, Mai HQ, Hong MH, Cui NJ, Lu TX, Lu LX, et al. Is the 1997 AJCC stag‑
ing system for nasopharyngeal carcinoma prognostically useful for Chi‑
nese patient populations? Int J Radiat Oncol Biol Phys. 2001;50(5):1181–9.
 4. Al‑Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemora‑
diotherapy versus radiotherapy in patients with advanced nasopharyn‑
geal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 
1998;16(4):1310–7.
 5. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, et al. 
Concurrent and adjuvant chemotherapy for nasopharyngeal carci‑
noma: a factorial study. J Clin Oncol. 2004;22(13):2643–53. doi:10.1200/
JCO.2004.05.173.
 6. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of 
radiotherapy versus concurrent chemoradiotherapy followed by adjuvant 
chemotherapy in patients with American Joint Committee on Cancer/
International Union against cancer stage III and IV nasopharyngeal cancer 
of the endemic variety. J Clin Oncol. 2005;23(27):6730–8. doi:10.1200/
JCO.2005.16.790.
 7. Lee AW, Tung SY, Chua DT, Ngan RK, Chappell R, Tung R, et al. Rand‑
omized trial of radiotherapy plus concurrent‑adjuvant chemotherapy vs 
radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J 
Natl Cancer Inst. 2010;102(15):1188–98. doi:10.1093/jnci/djq258.
 8. Lee AW, Tung SY, Chan AT, Chappell R, Fu YT, Lu TX, et al. A randomized 
trial on addition of concurrent‑adjuvant chemotherapy and/or acceler‑
ated fractionation for locally‑advanced nasopharyngeal carcinoma. 
Radiother Oncol. 2011;98(1):15–22. doi:10.1016/j.radonc.2010.09.023.
 9. Chen Y, Sun Y, Liang SB, Zong JF, Li WF, Chen M, et al. Progress report 
of a randomized trial comparing long‑term survival and late toxicity of 
concurrent chemoradiotherapy with adjuvant chemotherapy versus 
radiotherapy alone in patients with stage III to IV B nasopharyngeal 
carcinoma from endemic regions of China. Cancer. 2013;119(12):2230–8. 
doi:10.1002/cncr.28049.
 10. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, et al. How does intensity‑
modulated radiotherapy versus conventional two‑dimensional radio‑
therapy influence the treatment results in nasopharyngeal carcinoma 
patients? Int J Radiat Oncol Biol Phys. 2011;80(3):661–8. doi:10.1016/j.
ijrobp.2010.03.024.
 11. Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, et al. A prospective, 
randomized study comparing outcomes and toxicities of intensity‑
modulated radiotherapy vs. conventional two‑dimensional radiotherapy 
Page 9 of 9Qiu et al. Chin J Cancer  (2016) 35:2 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 
2012;104(3):286–93. doi:10.1016/j.radonc.2012.08.013.
 12. Liang Z, Zhu X, Li L, Qu S, Liang X, Liang Z, et al. Concurrent chemoradio‑
therapy followed by adjuvant chemotherapy compared with concur‑
rent chemoradiotherapy alone for the treatment of locally advanced 
nasopharyngeal carcinoma: a retrospective controlled study. Curr Oncol. 
2014;21(3):e408–17. doi:10.3747/co.21.1777.
 13. Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, et al. Long‑term 
survival after cisplatin‑based induction chemotherapy and radiotherapy 
for nasopharyngeal carcinoma: a pooled data analysis of two phase III 
trials. J Clin Oncol. 2005;23(6):1118–24. doi:10.1200/JCO.2005.12.081.
 14. Ouyang PY, Xie C, Mao YP, Zhang Y, Liang XX, Su Z, et al. Significant effica‑
cies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal 
carcinoma by meta‑analysis of published literature‑based randomized, 
controlled trials. Ann Oncol. 2013;24(8):2136–46. doi:10.1093/annonc/
mdt146.
 15. Zhao C, Han F, Lu LX, Huang SM, Lin CG, Deng XW, et al. Intensity 
modulated radiotherapy for local‑regional advanced nasopharyngeal 
carcinoma. Ai Zheng. 2004;23(11 Suppl):1532–7 (in Chinese).
 16. ICRU report 50. Available at: http://www.icru.org/home/reports/
prescribing‑recording‑and‑reporting‑photon‑beam‑therapy‑report‑50.
 17. ICRU report 62. Available at: http://www.icru.org/home/reports/
prescribing‑recording‑and‑reporting‑photon‑beam‑therapy‑report‑62.
 18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, 
et al. New response evaluation criteria in solid tumours: revised RECIST 
guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. doi:10.1016/j.
ejca.2008.10.026.
 19. Common terminology criteria for adverse events v3.0. Available at: http://
www.eortc.be/services/doc/ctc/ctcaev3.pdf.
 20. Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, et al. 
Head and neck cancers, version 2.2013 featured updates to the NCCN 
guidelines. J Natl Compr Cancer Netw. 2013;11(8):917–23.
 21. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, et al. Concur‑
rent chemotherapy–radiotherapy compared with radiotherapy alone 
in locoregionally advanced nasopharyngeal carcinoma: progression‑
free survival analysis of a phase III randomized trial. J Clin Oncol. 
2002;20(8):2038–44.
 22. Lin S, Lu JJ, Han L, Chen Q, Pan J. Sequential chemotherapy and intensity‑
modulated radiation therapy in the management of locoregionally 
advanced nasopharyngeal carcinoma: experience of 370 consecutive 
cases. BMC Cancer. 2010;10:39. doi:10.1186/1471‑2407‑10‑39.
 23. Su SF, Han F, Zhao C, Huang Y, Chen CY, Xiao WW, et al. Treatment 
outcomes for different subgroups of nasopharyngeal carcinoma patients 
treated with intensity‑modulated radiation therapy. Chin J Cancer. 
2011;30(8):565–73. doi:10.5732/cjc.010.10547.
 24. Ji X, Xie C, Hu D, Fan X, Zhou Y, Zheng Y. Survival benefit of adding chem‑
otherapy to intensity modulated radiation in patients with locoregion‑
ally advanced nasopharyngeal carcinoma. PLoS One. 2013;8(2):e56208. 
doi:10.1371/journal.pone.0056208.
 25. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation 
predicts radiation response in advanced squamous cell carcinoma of the 
head and neck. Radiother Oncol. 1996;41(1):31–9.
 26. Wang R, Wu F, Lu H, Wei B, Feng G, Li G, et al. Definitive intensity‑
modulated radiation therapy for nasopharyngeal carcinoma: long‑term 
outcome of a multicenter prospective study. J Cancer Res Clin Oncol. 
2013;139(1):139–45. doi:10.1007/s00432‑012‑1313‑0.
 27. Wu F, Wang R, Lu H, Wei B, Feng G, Li G, et al. Concurrent chemoradiother‑
apy in locoregionally advanced nasopharyngeal carcinoma: treatment 
outcomes of a prospective, multicentric clinical study. Radiother Oncol. 
2014;112(1):106–11. doi:10.1016/j.radonc.2014.05.005.
 28. Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in 
the management of advanced nasopharyngeal carcinoma. Cancer. 
2005;103(1):22–31. doi:10.1002/cncr.20768.
 29. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 
2005;365(9476):2041–54. doi:10.1016/S0140‑6736(05)66698‑6.
 30. Xu T, Zhu G, He X, Ying H, Hu C. A phase III randomized study comparing 
neoadjuvant chemotherapy with concurrent chemotherapy combined 
with radiotherapy for locoregionally advanced nasopharyngeal carci‑
noma: updated long‑term survival outcomes. Oral Oncol. 2014;50(2):71–
6. doi:10.1016/j.oraloncology.2013.11.002.
 31. Cheng SH, Jian JJ, Tsai SY, Yen KL, Chu NM, Chan KY, et al. Long‑term sur‑
vival of nasopharyngeal carcinoma following concomitant radiotherapy 
and chemotherapy. Int J Radiat Oncol Biol Phys. 2000;48(5):1323–30.
 32. Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, et al. Long‑term outcomes of 
intensity‑modulated radiotherapy for 868 patients with nasopharyngeal 
carcinoma: an analysis of survival and treatment toxicities. Radiother 
Oncol. 2014;110(3):398–403. doi:10.1016/j.radonc.2013.10.020.
 33. Yoshizaki T, Kondo S, Murono S, Endo K, Tsuji A, Nakanishi Y, et al. Progress 
and controversy for the role of chemotherapy in nasopharyngeal carci‑
noma. Jpn J Clin Oncol. 2015;45(3):244–7. doi:10.1093/jjco/hyu212.
